Biotech | November 20, 2021
Novo Nordisk to acquire Dicerna Pharmaceuticals for US $ 3.3 bn
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
The initiative will engage adolescents and youth of India in decisions about their reproductive health
The company performed particularly well in operational eco-efficiency, environmental and social reporting
The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence
The company is a medical dictation solution used by medical practitioners
The combined entity will have 12 hospitals with 3,666 beds
Key takeaways of recent quarter & conference call highlights
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
Through this initiative, the Centre for Trauma will create curriculums and facilitate trauma-related courses for healthcare professionals at both urban and grassroot levels
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Subscribe To Our Newsletter & Stay Updated
